Table 2 CHESS demographic data
From: The cost of severe haemophilia in Europe: the CHESS study
Country | ||||||
|---|---|---|---|---|---|---|
France (N = 272) | Germany (N = 194) | Italy (N = 280) | Spain (N = 218) | UK (N = 321) | CHESS (N = 1,285) | |
PSCs received (%) | 199 (73%) | 97 (50%) | 123 (44%) | 96 (44%) | 37 (12%) | 552 (43%) |
Haemophilia subtype (%) | ||||||
A | 202 (74%) | 153 (79%) | 219 (78%) | 176 (81%) | 246 (77%) | 996 (78%) |
B | 70 (26%) | 41 (21%) | 61 (22%) | 42 (19%) | 75 (23%) | 289 (22%) |
Age (mean (SD)) | 36.3 (13.7) | 31.1 (12.0) | 38.9 (15.5) | 36.0 (14.1) | 36.0 (15.9) | 35.9 (14.7) |
Age categories (%) | ||||||
18–35 | 154 (57%) | 135 (70%) | 142 (51%) | 123 (56%) | 192 (60%) | 746 (58%) |
36–59 | 95 (35%) | 52 (27%) | 100 (36%) | 78 (36%) | 91 (28%) | 416 (32%) |
60+ | 23 (8%) | 7 (4%) | 38 (14%) | 17 (8%) | 38 (12%) | 123 (10%) |
Treatment strategy: Prophylaxis (%) | 159 (58%) | 117 (60%) | 143 (51%) | 143 (66%) | 175 (55%) | 737 (57%) |
Inhibitor history (%) | ||||||
Never | 225 (83%) | 165 (85%) | 233 (83%) | 179 (82%) | 289 (90%) | 1,091 (85%) |
Previously | 29 (11%) | 25 (13%) | 38 (14%) | 27 (12%) | 17 (5%) | 136 (11%) |
Currently | 18 (7%) | 4 (2%) | 9 (3%) | 12 (6%) | 15 (5%) | 58 (5%) |
Patients with coinfection (%) | ||||||
HIV | 2 (1%) | 4 (2%) | 4 (1%) | 9 (4%) | 19 (6%) | 38 (3%) |
HCV | 7 (3%) | 5 (3%) | 22 (8%) | 15 (7%) | 21 (7%) | 70 (5%) |
EQ-5D-3 L index score (mean (SD)) | 0.73 (0.30) | 0.90 (0.12) | 0.84 (0.12) | 0.63 (0.37) | 0.59 (0.36) | 0.76 (0.28) |